Combination treatment for vivax malaria relapse prevention
Part of Infections clinical trials.
This trial tests whether combining tafenoquine with other malaria medicines works better than a single drug for curing vivax malaria and preventing it from coming back. You would receive the study drugs and be monitored for about 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old (male or non-pregnant, non-breastfeeding female).
- Have a confirmed vivax malaria infection with a certain level of parasites in the blood (measured by a blood smear).
- Have a normal level of an enzyme called G6PD in your blood (a simple blood test).
- Agree to contact the study team if you develop a fever during the 6-month follow-up, rather than seeking outside care first.
- Not have had a heart rhythm problem (like long QTc), or a family history of sudden cardiac death.
- Not have significant liver, kidney, or blood problems, and be free of active psychosis or severe malaria symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of three malaria drugs in healthy adults to see how safe they are and how the body handles them. It helps find the right dose for future patients.
This study gives healthy volunteers a controlled infection with a type of malaria (vivax) to see how the infection behaves and how well curative anti-malaria medicine works. It may help researchers better design and test future malaria vaccines and treatments.
This study tests a new combination of two medicines, SJ733 and tafenoquine, to see if it can safely and quickly cure vivax malaria. Vivax malaria can come back, so this treatment aims to prevent that relapse.
This trial tests a combination of antimalarial drugs (tafenoquine plus artemisinin-based combination therapies) to see if it's safe and effective for treating vivax malaria. Participating may help clear the infection and prevent it from coming back.
This study tests how well a malaria treatment plan works for people with P. vivax malaria who don’t have another malaria type at the same time. It aims to see whether adding or using different medicines (ACT vs chloroquine with tafenoquine) helps clear infection and prevent return of disease.
This trial tests a shorter course of the drug primaquine to prevent relapse of vivax malaria, a recurring type of malaria. It may offer a faster recovery with fewer doses.
Hear when a new Uncomplicated P. Vivax Mono-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.